Bevacizumab


Other name

BTD00087, BIOD00087

International/Other brands

Avastin

Groups

Approved

Structure

Prescription products

NameDosageStrengthRouteLabeller
AvastinSolution25 mgIntravenousHoffmann La Roche
AvastinInjection, solution400 mg/16mLIntravenousGenentech, Inc.
AvastinInjection, solution100 mg/4mLIntravenousGenentech, Inc.

Target

-

Description

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

Indications

As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.

Other indications

-

Mechaism of action

-

Absorption

-

Metabolism

Most likely removed by opsonization via the reticuloendothelial system when bound to endothelial cells, or by human antimurine antibody production

Toxicity

Category C in pregnancy. No studies on lactating patients: recommended to discontinue the drug or discontinue lactation. No extensive studies in pediatrics. In geriatrics: increased risk of proteinuria, arterial thromboembolic events, as well as GI bleeding and sepsis among others.